Merck & Co., Inc. sees the individualized neoantigen therapy mRNA-4157, also known as V940, as a key pillar in its oncology development strategy over the next several years, which it said could deliver incremental sales of $20bn by the middle of the next decade, particularly after the presentation of positive follow-up data at the American Society of Clinical Oncology annual meeting.
ASCO: Merck Calls V940 IO Strategy ‘Pillar’ Amid Positive Melanoma Data
Follow-up data from Merck & Co./Moderna’s KEYNOTE-942 showed durable responses to V940/Keytruda, while Merck said the therapy plays a leading role in its immuno-oncology strategy.
